Nascent Biotech Inc 's ROA from the first quarter of 2025 to the first quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Nascent Biotech Inc 's ROA in the first quarter of 2025?
Nascent Biotech Inc recorded a cumulative net loss of $-2 million during 12 months ending in the first quarter of 2025, resulting in a negative return on assets (ROA) of -312.49%.

However, within the Healthcare sector 1010 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2024 quarter, so far to 5096, from total ROA ranking in the fourth quarter of 2024 at 5894.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2024) I. Quarter	(Mar 31 2024) IV. Quarter	(Dec 31 2023) III. Quarter	(Sep 30 2023) II. Quarter	(Jun 30 2023) I. Quarter
Y / Y Total Assets Change	188.04 %	116.52 %	13.4 %	-13.18 %	-56.94 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-2	-2	-2	-3	-2
Return On Assets (TTM)	-312.49 %	-360.65 %	-414.84 %	-561.15 %	-388.67 %
NBIO's Total Ranking	# 5096	# 5894	# 5338	# 5421	# 5582
Total Assets (TTM) in million	0	1	1	1	0
Seq. Total Assets Change	-58.82 %	-13.96 %	-38.46 %	1220.76 %	-69.04 %
Seq. Net Income Change	-	-	-	-	-

NBIO's 5 Years Annual ROA >> Back to NBIO Management Effectiveness >> Compare NBIO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 486
Sector	# 1011
Overall	# 4972

Return On Assets Statistics
High	Average	Low
156.22 %	-8209.89 %	-143853.24 %
(Dec 31 2015)		(Jun 30 2020)

Financial Statements
Nascent Biotech Inc 's Assets	$ 0 million	NBIO's Balance sheet
Nascent Biotech Inc 's Income	$ 0 million	Quarterly NBIO's Income Statement
NBIO's Income by Division		See NBIO's Income by Division

Annual Return On Assets	(Mar 31 2024) FY 2024	(Mar 31 2023) FY 2023	(Mar 31 2022) FY 2022	(Mar 31 2021) FY 2021	(Mar 31 2020) FY 2020
Y / Y Total Assets Change	116.52 %	141.88 %	-85.97 %	23122.19 %	-97.54 %
Total Assets in million	1	0	0	1	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-2	-3	0	-1	-4
Annual Return On Assets	-378.11 %	-1098.4 %	-446.17 %	-127.59 %	-123737.73 %

NBIO's 5 Years Annual ROA >> Back to NBIO Management Effectiveness >> Compare NBIO ROA to its Competitors

More Return On Assets Ratios
NBIO's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NBIO's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NBIO's Competitors
Subscribers only: Roa for Nascent Biotech Inc 's Suppliers
Subscribers only: Return On Assets for NBIO's Customers

You may also want to know
NBIO's Roi	NBIO's Inventory Turnover Ratio	NBIO's Growth Rates	NBIO's Dividend Comparisons
	NBIO's Profitability Ratios	NBIO's Asset Turnover Ratio	NBIO's Dividend Growth
NBIO's Roe	NBIO's Valuation Ratios	NBIO's Financial Strength Ratios	NBIO's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2024, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.